Jiangxi Rimag Group (HKG:2522) expects to incur a net loss of between 55 million yuan and 60 million yuan in 2024, swinging from the year-ago profit of 36.6 million yuan, according to a Hong Kong Stock Exchange filing on Tuesday.

The medical imaging solution services company attributed the forecasted loss to the macroeconomic environment and a slowdown in demand, as well as the incurrence of certain expenses.

The actual financial results are set to be published on or before March 31, the filing said.

The company's shares closed less than 4% higher.